DexCom, Inc. DXCM
NASDAQ · Healthcare · Medical - Devices
$79.32
Close on Fri, 20 Nov 2026 · market value $29.6B
What the price is betting on
In line with its recordAt $79, the price assumes revenue grows about 15% a year for five years, from $5.1B to about $9.2B by FY2030. That is about one and a half times what analysts expect for the next two years and about the same as the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 10% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than DXCM? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$51
Base
$66
Bull
$80
Today $79
- Bear $51. Growth keeps slowing below the latest quarter's pace as competitors and reimbursement bite. Gross margin keeps eroding, as it has for four years with no sign of pricing power, so cash flow grows more slowly than sales and than analysts expect. A premium-priced stock then loses its premium.
- Base $66. Sales keep growing near the latest quarter's pace, and gross margin stops falling from its current level. Operating leverage keeps cash flow tracking sales, so cash flow grows about as fast as analysts expect before fading to a long-run rate.
- Bull $80. New uses for G7 and partnerships such as Beta Bionics and the Canadian pregnancy approval lift sales growth back toward last year's pace. Operating leverage, seen in the latest quarter's profit rise, keeps turning that growth into cash, and gross margin stops sliding, so cash flow grows faster than analysts expect.
AI-written stories, valued by code from the same model.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$5.3B$5.2B, on the path
- FY2027$6.1B$5.8B, below the path
- FY2028$7B$6.4B, below the path
- FY2029$8B$7.1B, below the path
- FY2030$9.2B$7.8B, below the path
Each year's revenue at 15% growth from $5.1B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Devices · listed on NASDAQ
- Revenue, FY2025
- $4.7B
- Growth, 3 years a year
- 13%
- Cash margin
- 23%
- Net cash
- $609M
- Shares, 3-year change
- −5.1%
- Dividend yield
- 0%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.